Stand UP to Rheumatoid Arthritis (SUPRA) (SUPRA)
Rheumatoid Arthritis
About this trial
This is an interventional other trial for Rheumatoid Arthritis focused on measuring Rheumatoid arthritis, Pragmatic trials, Feasibility
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years;
- Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA;
- Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2).
Exclusion Criteria:
- Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2;
- Contraindication to b/tsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation;
- Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis;
- Unable to provide consent or complete forms (alone or with assistance) in English or French
Sites / Locations
- Sir Mortimer B. Davis Jewish General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Sub-study 1 TNFi
Sub-study 1 Anti-IL6
Sub-study 2 Anti-IL6
Sub-study 2 JAKi
TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein), adalimumab (monoclonal antibody), golimumab (monoclonal antibody), or certolizumab (pegylated fragment of a monoclonal antibody)
Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab
JAKi - tofacitinib (JAK1/3 inhibitor), baricitinib (JAK 1/2 inhibitor) or upadacitinib (JAK1 inhibitor)